 The wonders of the biotech revolution will be a result of the fusing of technology, engineering and medicine to create a new world of health diagnosis. One com-pany that is embracing the technological aspect of this revolution is CellaVision. The Swedish company is aiming to be the world’s leading cell and tissue analysts using digital image-processing technology. |
 CellaVision AB Founded: 1994 Publicly listed: No Number of employees: 45 Key business area(s): Medical technology Telephone. +46 46 286 44 00 Website Contact |
|
|
| A
new vision of research “Today, 2-3 billion microscopy analyses are performed each year by health-care professionals worldwide,” says CellaVision CEO Yvonne Mårtensson. “Of these, more than 200 million are manual classifications of white blood cells. We are automating this process.” DiffMaster™ and CellAtlas™ Based in the University town of Lund, the company was founded in 1994 and currently has 39 close to 50 employees developing software products. The company currently offers two software-products - ‘DiffMaster™’ for automatically analysing white blood cells and CellAtlas™ - a web-based tool that simplifies cell analysis and diagnosis and provides training. Diffmaster in particular has been a major breakthrough in liberating scientists med techs to concentrate on the more important aspects of their analysis of white bloodcellsresearch says Mårtensson. Frees researchers “The biggest asset our products offer is time-savings and standardization. Computerized analysis of blood samples free researchers and med techs to concentrate on more important things. “However, the scientist med tech will always get the final say so the human element is not entirely removed,” stresses Mårtensson. The biotech industry needs this The biotech industry won’t merely welcome this technology, it positively needs it. In both Sweden and USA, the average age of medical research scientistslaboratory skilled people is 48 years-old and half of these will be retired within the next ten years. But CellaVision don’t intend to sit on their laurels. Mårtensson has some ambitious plans in store for the company. “Trends indicate that the market for microscopy analysis will become automated in the long run. Hematology (the study of blood) is an important field for automated microscopy but our next step is to develop applications for hospital labs specializing in histopathology and cytology.” Nicholas Mead |
All Rights Reserved